Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001437749-24-038167
Filing Date
2024-12-20
Accepted
2024-12-20 17:32:09
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 29778
2 JOINT FILING AGREEMENT exhibit1.htm EX-1 7636
  Complete submission text file 0001437749-24-038167.txt   39190
Mailing Address 125 STRAFFORD AVE SUITE 360 WAYNE PA 19087
Business Address 125 STRAFFORD AVE SUITE 360 WAYNE PA 19087 (484) 253-1461
PALVELLA THERAPEUTICS, INC. (Subject) CIK: 0001583648 (see all company filings)

EIN.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-88917 | Film No.: 241569090
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O PALVELLA THERAPEUTICS 125 STRAFFORD DRIVE WAYNE PA 19087
Business Address
Kaupinen Wes (Filed by) CIK: 0001918142 (see all company filings)

Type: SCHEDULE 13D